FAQ

Cancer Therapy Evaluation Program

Known as: CTEP 
The program within the Division of Cancer Treatment and Diagnosis (DCTD) of the NCI which plans, assesses, and coordinates all aspects of clinical… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1975-2018
05101519752018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability. Previous studies have implicated mGlu5 in… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
2011
2011
CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
The metabotropic glutamate receptor 5 (mGlu5) is a glutamate-activated class C G protein-coupled receptor widely expressed in the… (More)
  • table 1
  • figure 1
  • table 3
  • figure 3
  • figure 4
Is this relevant?
2010
2010
A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
PURPOSE Postactivation barriers to oncology clinical trial accruals are well documented; however, potential barriers prior to… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
BACKGROUND Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2004
2004
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia
Activating mutations in the RAS oncogenes are among the most common genetic alterations in human cancers, including patients with… (More)
  • figure 1
  • table 1
  • figure 5
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
PURPOSE To determine the changes in clinical trials and outcomes of patients with advanced-stage non-small-cell lung cancer… (More)
Is this relevant?
2001
2001
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report.
PURPOSE To report the preliminary results of a Phase I/II study combining radiotherapy and in situ gene therapy (adenovirus… (More)
Is this relevant?
2000
2000
Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.
PURPOSE We assess risks, toxicity and side effects of multiple and repeat in situ suicide gene therapy in patients with localized… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.
PURPOSE All cooperative group studies performed in North America for patients with extensive-stage small-cell lung cancer (SCLC… (More)
Is this relevant?